Introduction: Fingolimod 0.5 mg is an orally active sphingosine 1-phosphate receptor
fingolimod due to AEs. Infections were reported in 33 patients (23.9%) and were predominantly mild in nature (n = 28, 20.3%). Increases in alanine aminotransferase enzymes of C3, C5 and C10 upper limit of normal were reported in five (3.7%), three (2.2%) and one (0.7%) patients, respectively. Hypertension cases (n = 3; 2.2%) did not result in treatment discontinuation and were controlled with antihypertensive therapy. Following first-dose administration, the majority of patients (90.6%) were discharged at 6 h. During the first-dose monitoring, 5 cases of bradycardia were reported; none required extended monitoring or treatment for symptomatic bradycardia.
INTRODUCTION
Multiple sclerosis (MS) is one of the most common, autoimmune, inflammatory, demyelinating diseases of the central nervous system in young adults, affecting approximately 2.3 million people worldwide [1, 2] . Differences in the risk of MS and the disease course have been reported earlier in the Latin American population as compared to the well-studied Caucasian population [3] [4] [5] [6] [7] [8] . For example, the Latin American MS population has higher age at disease onset and slower rate of progression of disability over time [4] . Furthermore, there is growing evidence suggestive of an increased frequency of MS incidence in this region, attributable mainly to the improved awareness of the disease [4, 8] . The expansion of treatment options for relapsing-remitting MS (RRMS), including high efficacy agents, offers the possibility of controlling suboptimal disease activity [8] . The availability of ethnically relevant clinical evidence is important for clinical management at the individual patient level [8] .
Once-daily oral fingolimod 0.5 mg (Gilenya TM , Novartis Pharma AG, Basel, Switzerland) is a first-in class sphingosine 1-phosphate receptor modulator approved for the treatment of relapsing forms of MS with a well-characterized efficacy and safety profile in a large clinical development program [9] [10] [11] [12] .
The safety and tolerability in the Hispanic patients were consistent with the overall study population in the fingolimod clinical trial program [13] . Smaller studies at country level in the region have provided further evidence of the safety and tolerability of fingolimod use in MS patients from Latin America; however, more comprehensive data on first-dose observation are still lacking [13] [14] [15] [16] .
The present study was aimed to provide additional data on the short-term safety and tolerability of fingolimod in more ethnically relevant MS patient population in Latin American countries. All patients received the first dose of fingolimod and were monitored for at least 6 h post-dose. First-dose monitoring included an ECG at baseline and at 6 h as well as hourly sitting heart rate (HR) and blood pressure (BP) monitoring. Patients were asked to inform the investigator about any cardiac symptoms or other AEs. The initial discharge criteria after 6 h of cardiac monitoring were: HR C51 bpm, HR [80% of baseline value and was not the lowest hourly value, absence of symptoms associated with decreased HR, and ECG at 6 h showing no new significant ECG abnormalities. During the course of the study, following a regulatory authority review, revisions were made to fingolimod labeling and prescribing guidance; consequently, amendments were made to cardiac exclusion and first-dose discharge criteria in the study (extended monitoring required for HR\45 bpm, symptomatic or received treatment for bradycardia, lowest hourly HR, new-onset second-degree or higher atrioventricular block (AVB), QTc C500 ms at 6 h).
METHODS

Study Population and Study Design
Statistical Analysis
Primary variables were summarized using descriptive statistics. Categorical variables were presented as numbers and percentages.
Continuous variables were summarized as number, mean, standard deviation, and minimum and maximum values. The ECG parameters, vital signs and laboratory data were summarized as mean change from baseline values by visit. All the analyses were performed using SAS 9.3 (The SAS Institute, Cary, NC, USA).
RESULTS
Subject Disposition and Demographic and Clinical Characteristics
The FIRST LATAM study enrolled 162 patients, A majority of patients (66%) were on medications or non-drug therapies prior to the start of study drug. The most common prior concomitant medications were gabapentin (9.9%), paracetamol (9.9%), omeprazole (8.0%), and cholecalciferol (5.6%). Concomitant medications administered after the start of study medication were taken by 80.9% of patients. The most common concomitant medications were paracetamol (18.5%), omeprazole (11.7%), gabapentin (10.5%), and ibuprofen (9.9%).
Corticosteroids, like methylprednisolone and ethylprednisolone sodium, were permitted by the protocol for MS relapses and were received by 3.7% and 3.1% of the patients, respectively. Of the patients who had received prior MS treatment (70%), most common were the interferon beta therapies (55.6%) and glatiramer acetate (14.8%).
Overview of AEs and SAEs
Overall, AEs were predominantly mild (n = 49, 142). This event occurred after the patient had discontinued the study and no further records on vital signs are available. All these events were predominantly mild in nature and none were serious or led to study drug discontinuation.
Mean (±SD) changes from baseline in systolic and diastolic BP were 3.4 (±10.3) and 2.5 (±7.5)
mmHg. All three cases of hypertension (n = 3; 2.2%) were managed with antihypertensive therapy and did not result in treatment discontinuation. No case of macular edema was reported in the study.
First-Dose Observations
The majority of patients (90.6%) were discharged at 6 h ( Table 2 ). With continued treatment, the mean HR returned to baseline levels ( Fig. 1) and by week 16, the decrease in mean (±SD) HR was -1.08 (±8.66) bpm relative to the pre-dose baseline mean value. A small decrease in BP was observed which returned to baseline by 6 h: peak time/mean changes [mmHg (±SD): systolic (between 3 and 5 h) Safety data from the overall study population (n = 162) were comparable to the findings presented here for the LATAM population (n = 138) in the study (Data not shown). AEs adverse events, ALT alanine transaminase, AP alkaline phosphatase, AST aspartate transaminase, Bi bilirubin, BP blood pressure, GGT gamma glutamyl transferase, N no. of patients, SAEs serious adverse events, SD standard deviation a SAEs: MS relapses (n = 3; severity: 2 mild, 1 moderate);
D-fibrin increased (n = 1; no associated clinical abnormality); gastroenteritis (n = 2; severity: 1 mild, 1 severe) b A minority of bradyarrhythmia AEs were reported after first dose (days 23-142): dizziness 3; bradycardia 1; presyncope 1; malaise 2; hypotension 1 c Thromboembolic AEs: 1 (0.7%) case each of monoparesis and angina pectoris. Monoparesis was of moderate severity and was not suspected by the investigator to be related to the study medication. Angina pectoris was of mild severity, suspected to be related to study drug medication. Neither AE resulted in study drug discontinuation d No. of patients for whom measurements were available
DISCUSSION
In the FIRST LATAM study, we investigated the short-term safety and tolerability of fingolimod 0.5 mg dose in a Latin American MS patient population. The overall safety profile was consistent with previous clinical trial experience, particularly the larger FIRST study (n = 2415) of comparable duration, with no new or unexpected safety signals [20, 21] .
Overall, fingolimod was well tolerated in the study population. Only three patients discontinued treatment due to AEs, of whom two discontinued due to persistently elevated bilirubin and GGT levels (C2 ULN) and one discontinued due to an AE (erythema nodosum). AEs were generally reported as mild to moderate in nature, with the most common AEs being headache and fatigue. The overall nature and frequency of the AEs, including the specific safety areas of interest (namely infections, liver enzyme elevation, BP changes, and macular edema) were consistent with the previous experience [20, 21] . The majority of infections were mild with upper respiratory tract infections being the most common. The incidence of herpes zoster infection was low; no disseminated cases were reported. The reported case of herpes zoster infection was considered mild in severity and suspected to be related to Severe 0
AEs adverse events, AV atrioventricular, ECG electrocardiogram, HR heart rate, N no. of patients a First-dose monitoring guidance was updated during the course of the study, removing criteria for HR at discharge must be [80% of the baseline value and for repeat monitoring on day 2 if HR decreases by [30% from baseline at any time during the 6-h monitoring on day 1, and adding criteria on requirement of extended first dose monitoring if QTc C 500 msec at 6 h b One patient reported dizziness alone without bradycardia. One patient reported bradycardia and hypotension on day 1 Fig. 1 Hourly mean change in heart rate (HR) in 6 h following first dose and at 4 months. SD standard deviation
The first dose of fingolimod, in this current study, was well tolerated with transient, mostly asymptomatic decreases in HR, which were consistent with previous clinical trial experience and are attributed to the pharmacodynamic properties of fingolimod [22] . The majority of patients were discharged at 6 h, while a minority of patients underwent extended monitoring to ensure that protocol mandated HR recovery criteria were met. No abnormal ECG findings were reported and no patient discontinued treatment following the first-dose procedure. Although, in contrast to the larger FIRST study, bradycardia was reported in proportionally higher number of patients in this study (3.6% versus 0.6%) [20, 22] No patient discontinued the treatment following the first dose [13] . Similar to our current study, first-dose fingolimod experience from a single Chilean center (n = 78) was reported to be well tolerated; there were no reports of symptomatic bradycardia and all patients were discharged at 6 h [15] . Similarly, the preliminary analysis of a multi-center, prospective study in Argentina (n = 92) demonstrated a well-tolerated cardiac safety profile of fingolimod. Extended monitoring due to prolonged bradycardia was required in three patients; however, none of the patients developed symptomatic bradycardia [16] . In a retrospective chart review of first-dose experience from several Brazilian clinics (n = 180 RRMS patients), 99.4% of patients continued fingolimod treatment after the initial dose, and extended monitoring due to symptomatic bradycardia was required for 12 patients (6.7%) [14] .
The results of the short-term FIRST LATAM study provide ethnically relevant Latin American patient data, which are consistent with the results from the overall fingolimod clinical trial program. Further longer term follow-up in such patient cohorts will provide more information to further aid clinical decision making in Latin America.
CONCLUSION
Overall, the FIRST LATAM study demonstrates that the first dose of fingolimod 0.5 mg is well tolerated, the pharmacodynamic effects are consistent with previous findings, and fingolimod has a clinically manageable safety profile in Latin American RRMS patients. 
